- Srivastava, Sudhir — National Cancer Institute
- Troyer, Dean — Eastern Virginia Medical School
- Lin UW, Daniel W. — University of Washington
- Listwin, Don — Canary Foundation
- Brooks, James D. — Stanford University Medical Center
- Carroll, Peter R. — University of California, San Francisco
- Nelson, Peter S — Fred Hutchinson Cancer Research Center
- Gleave, Martin — University of British Columbia
- Thompson, Ian M. — University of Texas Health Science Center at San Antonio
- Feng, Ziding — Fred Hutchinson Cancer Research Center
This protocol describes a multi-center, retrospective, case-cohort tissue microarray (TMA) study to evaluate tissue biomarkers for their ability to predict recurrent prostate cancer at the time of radical prostatectomy (RP). Candidate biomarkers will be assessed by performing tissue localization studies on TMAs containing recurrent prostate cancer and non-recurrent prostate cancer. De-identified data will be transferred to a central repository for statistical analysis. Participating institutions will use a variation of case-cohort sampling to randomly select a subset of patients from a retrospectively constructed RP cohort and/or perform selected assays on the cohort. The study endpoint is time to recurrence; of primary interest is five year recurrence free survival. Recurrent prostate cancer is defined by 1) a single serum prostate-specific antigen (PSA) level greater than 0.2 ng/mL after RP and/or 2) receipt of salvage or secondary therapy after RP and/or 3) clinical or radiological evidence of metastatic disease. Non-recurrent prostate cancer is defined as disease with no evidence of recurrence.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.